Medicine Press release

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep"
More info..

Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. According to reports, on the day the first prescription was issued in mainland China, VELSIPITY(R) was simultaneously prescribed in eight tertiary hospitals across seven key cities'Guangzhou, Shanghai, Hangzhou, Xi'an, Chongqing, Beijing, and Nanjing'achieving immediate coverage of patients in major regions nationwide on its launch day.
More info..

Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online.
More info..

Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online.
More info..

Fujitsu Limited and DT-Axis Co., Ltd. today announced the commencement of a collaboration aimed at advancing digital health. The two companies have signed a memorandum of understanding to provide comprehensive support for the development of Software as Medical Device (SaMD), including regulatory approval and sales, for research and development institutions, as well as medical device and pharmaceutical companies.
More info..

As International Women's Day prompt renewed focus on women's health, OMRON Healthcare has released a new Women's Heart Health Factbook spotlighting an often-overlooked issue: the intersection between menopause, hypertension, and long-term cardiovascular risk.
More info..

As International Women's Day prompt renewed focus on women's health, OMRON Healthcare has released a new Women's Heart Health Factbook spotlighting an often-overlooked issue: the intersection between menopause, hypertension, and long-term cardiovascular risk.
More info..

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy.
More info..

Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company said in a filing.
More info..

Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company said in a filing.
More info..